HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


TAP Licenses Prevacid To Novartis For 2009 Switch

This article was originally published in The Tan Sheet

Executive Summary

Novartis is developing TAP's Prevacid prescription heartburn and GERD therapy for a 2009 switch to OTC status, the firms announced Dec. 20

Related Content

TAP buyout leaves Prevacid switch deal intact
Zegerid May Bring Quick Heartburn Relief To Market Under Santarus/S-P deal
Excedrin Migraine Has Untapped Growth Potential, Novartis Says
JAMA Study Links Gastric Acid-Suppressing Drugs To Increased Diarrhea Risk
Bristol/Novartis deal
Novartis Purchase Of Bristol OTCs Has Excedrin Written All Over It
Prevacid NapraPAC Scripts Suggest PPI/NSAID Combos May Thrive Post-Vioxx
Prilosec OTC Sales Top The $400 Mil. Mark; Prevacid Feeling The Burn
Prilosec OTC Making Inroads Into Abbott’s Prevacid
Prilosec OTC Approved In 28-, 42-Count Multiple Regimen Sizes





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts